TRxADE HEALTH Inc. (NASDAQ:MEDS) shares, rose in value on Wednesday, 07/21/21, with the stock price up by 6.55% to the previous day’s close as strong demand from buyers drove the stock to $5.69.
Actively observing the price movement in the last trading, the stock closed the session at $5.34, falling within a range of $5.50 and $8.05. The value of beta (5-year monthly) was 1.11. Referring to stock’s 52-week performance, its high was $10.82, and the low was $3.10. On the whole, MEDS has fluctuated by 29.91% over the past month.
With the market capitalization of TRxADE HEALTH Inc. currently standing at about $48.76 million, investors are eagerly awaiting this quarter’s results, scheduled for Jul 26, 2021 – Jul 30, 2021. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.09, which is expected to increase to -$0.03 for fiscal year -$0.24 and then to about $0.38 by fiscal year 2022. Data indicates that the EPS growth is expected to be -4.30% in 2022, while the next year’s EPS growth is forecast to be 258.30%.
Analysts have estimated the company’s revenue for the quarter at $2.27 million, with a low estimate of $2 million and a high estimate of $2.58 million. According to the average forecast, sales growth in current quarter could jump down -65.60%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $10.42 million, representing a decrease of -39.10% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that MEDS’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Buy.
3 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 3 recommend it as a Buy and 0 called the MEDS stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MEDS currently trading nearly 7.07% and 26.78% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 56.25, while the 7-day volatility ratio is showing 15.73% which for the 30-day chart, stands at 12.32%. Furthermore, TRxADE HEALTH Inc. (MEDS)’s beta value is 1.28, and its average true range (ATR) is 0.81. The company’s stock has been forecasted to trade at an average price of $9.42 over the course of the next 52 weeks, with a low of $7.25 and a high of $11.00. Based on these price targets, the low is -27.42% off current price, whereas the price has to move -93.32% to reach the yearly target high. Additionally, analysts’ median price of $10.00 is likely to be welcomed by investors because it represents a decrease of -75.75% from the current levels.
Data on historical trading for TRxADE HEALTH Inc. (NASDAQ:MEDS) indicates that the trading volumes over the past 3 months, they’ve averaged 5.01 million. According to company’s latest data on outstanding shares, there are 8.09 million shares outstanding.
Nearly 16.10% of TRxADE HEALTH Inc.’s shares belong to company insiders and institutional investors own 13.80% of the company’s shares. The stock has risen by 7.56% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MEDS stock heading into the next quarter.